AstraZeneca’s Ultomiris label expansion stalls after FDA rejects sBLA, asks for REMS changes
AstraZeneca’s rare disease asset Ultomiris was presented with a CRL for neuromyelitis optica spectrum disorder (NMOSD), as the FDA seeks tweaks to the monoclonal antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
